OakChart

Kyverna Therapeutics Inc

KYTXHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 11:14 AM ET

5.19+0.11 (2.17%)
2026-11-11 17:14 CET
Market cap
314.16 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-152.64 USD m
Free cash flow, TTM
-160.23 USD m
EPS diluted, TTM
-2.94
P/E
-
Compare

Price

KYTX against its 20, 50 and 200-day averages
2050200beat
6.008.0010.003.4M6.8MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26KYTXclose 5.1920-day 5.4650-day 6.36200-day 7.925.1952w low

62.0% under the 52-week high of 13.67 on 15 Dec 2025. 52-week low 4.50 on 5 Nov 2026. Last 15 sessions, 36.2% high to low

Profile

KYTX
52-week range, 8% of the way up
4.4913.67

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

IndexRUT
Employees130
IPOFeb 08, 2024
Beta2.15
ATR, 14d0.39
Rel volume0.59
Short float23.35%
Insider own37.02%
Inst own49.21%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap320.96M
Enterprise Value154.53M
Income-152.64M
Sales0.00M
Book/sh2.69
Cash/sh3.22
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees130
IPOFeb 08, 2024

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.93
P/C1.61
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio9.06
Current Ratio9.06
Debt/Eq0.20
LT Debt/Eq0.19
Option/ShortYes / Yes

Earnings

EPS (ttm)-2.94
EPS next Y-3.12
EPS next Q-0.69
EPS this Y24.15%
EPS next Y-12.84%
EPS next 5Y10.13%
EPS past 3/5Y-75.86% -56.27%
Sales past 3/5Y- -
EPS Y/Y TTM20.07%
Sales Y/Y TTM-
EPS Q/Q35.37%
Sales Q/Q-
EarningsAug 11 AMC
EPS/Sales Surpr.7.12% -

Ownership

Insider Own37.02%
Insider Trans0.00%
Inst Own49.21%
Inst Trans2.88%
ROA-68.40%
ROE-87.24%
ROIC-77.47%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-4.99%
SMA50-18.34%
SMA200-34.48%
Trades-

Technical

Shs Outstand61.57M
Shs Float38.95M
Short Float23.35%
Short Ratio10.59
Short Interest9.10M
52W High13.67 -62.03%
52W Low4.49 15.46%
Volatility8.97% 7.38%
ATR (14)0.39
RSI (14)41.34
Beta2.15
Rel Volume0.59
Avg Volume858.55K
Volume153,004

Performance

Perf Week0.58%
Perf Month-10.05%
Perf Quarter-35.77%
Perf Half Y-51.86%
Perf YTD-44.79%
Perf Year-25.86%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price30.40
Prev Close5.08
Price5.19
Change %2.17%

Analyst ratings

latest 9 of 9
DateActionAnalystRating changeTargetImplied
Aug 20, 2025InitiatedWWilliam BlairOutperform
May 27, 2025UpgradeHH.C. WainwrightNeutral → Buy$5-3.7%
Oct 10, 2024InitiatedUUBSBuy$13+150.5%
Oct 09, 2024InitiatedRRodman & RenshawBuy$16+208.3%
Jul 03, 2024InitiatedHH.C. WainwrightNeutral$8+54.1%
Mar 04, 2024InitiatedWWells FargoOverweight$44+747.8%
Mar 04, 2024InitiatedMMorgan StanleyOverweight$40+670.7%
Mar 04, 2024InitiatedLLeerink PartnersOutperform$48+824.9%
Mar 04, 2024InitiatedJJP MorganOverweight$39+651.4%

Peers

Mkt cap
TickerCompanyMkt cap
CABACabaletta Bio Inc305.24M
RNACCartesian Therapeutics Inc212.46M
ARTVArtiva Biotherapeutics Inc202.92M
AUTLAutolus Therapeutics plc ADR331.37M
SANASana Biotechnology Inc713.91M
FATEFate Therapeutics Inc204.85M
ALLOAllogene Therapeutics Inc312.34M
NKTXNkarta Inc96.44M
ARGXArgen X SE ADR61.09B
IMVTImmunovant Inc7.64B

Insider trading

9 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
KAREN WALKEROfficerApr 17 '26Proposed Sale9.5310,00095,300Apr 17 04:37 PM
KAREN WALKEROfficerApr 14 '26Proposed Sale9.492,45923,336Apr 14 04:38 PM
DANIEL SPIEGELMANDirectorApr 07 '26Proposed Sale9.2517,578162,637Apr 07 04:05 PM
DANIEL SPIEGELMANDirectorMar 31 '26Proposed Sale8.4416,634140,404Mar 31 05:09 PM
SEIDENBERG BETH CDirectorDec 18 '25Buy7.50133,333999,998869,317Dec 22 11:43 AM
Westlake BioPartners Opportuni10% OwnerDec 18 '25Buy7.50133,333999,998869,317Dec 22 11:42 AM
Walker Karen MarieChief Technology OfficerDec 15 '25Option Exercise4.8323,998115,91046,634Dec 17 08:30 PM
Walker Karen MarieChief Technology OfficerDec 15 '25Sale12.2023,998292,77622,636Dec 17 08:30 PM
KAREN WALKEROfficerDec 15 '25Proposed Sale8.7823,998210,702Dec 15 04:16 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IBBiShares Biotechnology ETFAUM: 11.36B
KOMPState Street SPDR S&P Kensho New Economies Composite ETFAUM: 2.46B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
SURISimplify Propel Opportunities ETFAUM: 74.30M

News

latest 14 of 206
  • Kyverna Therapeutics Announces Publication of Registrational Miv-cel Data in Patients with Stiff Person Syndrome in JAMA Neurology (GlobeNewswire) +5.94%
  • Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference (GlobeNewswire) -10.66% +5.86%
  • Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026 (GlobeNewswire) -5.93%
  • Did Kyverna Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire)
  • Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto (GlobeNewswire)
  • Loading…
  • Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026 (GlobeNewswire)
  • KYTX Stock Reverses Gains After One-Year Cell Therapy Trial Data But CEO Says Disease Burden Justifies A Premium Price (Stocktwits)
  • Kyverna stock jumps on positive one-year therapy data (Investing.com)
  • Kyverna Reports One-Year Miv-Cel Data From SPS and gMG Trials (InvestorsHub)
  • Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis (GlobeNewswire)
  • Kyverna Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
  • Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts (BioPharma Dive)
  • Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-11-0.630-0.678-0.6290.000.006
2026Q12026-05-12-0.660-0.752-0.6570.000.006
2025Q42026-03-26-0.800-0.851-0.8020.000.006
2025Q32025-11-12-0.850-0.971-0.8470.000.006
2025Q22025-08-12-0.970-1.044-0.9740.000.006
2025Q12025-05-13-1.030-1.126-1.0330.000.006
2024Q42025-03-27-0.868-0.841-0.8680.000.007
2024Q32024-11-13-0.800-0.814-0.7990.000.007
2024Q22024-08-12-0.670-0.698-0.6680.000.005
2024Q12024-05-14-1.120-0.840-1.1240.000.004
2023Q42024-03-26-20.535-0.703-0.4790.000.003
2026Q3---0.691--0.006
2026Q4---0.784--0.006
2027Q1---0.797--1.003
2027Q2---0.719--2.033
2027Q3---0.714--4.583

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2023FY-89.610-2.027-1.4000.000.00
2024FY-3.330-3.298-3.3250.000.00
2025FY-3.640-3.694-3.6400.000.00
2026FY--2.761--0.00
2027FY--3.116--17.20
2028FY--2.642--70.69
2029FY--3.610--174.55
2030FY--1.050--523.75

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-211000.000.000.00
2026Q3S2026-08-122000.000.000.00
2026Q3S2026-08-112000.000.000.00
2026Q3S2026-05-132000.000.000.00
2026Q3S2026-03-272000.000.000.00
2026Q3S2026-02-051000.000.000.00
2026Q3R2026-08-12100-0.70-0.70-0.70
2026Q3R2026-08-11100-0.70-0.70-0.70
2026Q3R2026-07-27100-0.70-0.70-0.70
2026Q3R2026-05-13110-0.70-0.70-0.70
2026Q3R2026-03-27100-0.86-0.86-0.86
2026Q3E2026-10-27600-0.69-0.77-0.65
2026Q3E2026-10-26610-0.69-0.77-0.65
2026Q3E2026-09-29640-0.69-0.77-0.65

Estimate history

EPS, annual-0.611-0.67-1.4-3.325-3.645-2.9356
Period20212022202320242025TTM
EPS, quarterly-0.668-0.799-0.868-1.033-0.974-0.847-0.802-0.657-0.629
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual5.6567.0250000
Period20212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual43.11543.11543.11543.21560.3961.57
Period20212022202320242025MRQ
Shares, quarterly43.14743.16743.21543.21943.24543.79460.3960.53361.57
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Total Revenue0.000.000.000.007.035.66
Cost of Goods Sold Incl. D&A1.571.802.131.711.050.59
Gross Profit-1.57-1.80-2.13-1.715.975.07
Selling, General and Administrative Excl. Other157.36167.38140.4760.7035.3631.42
Research and Development113.76131.27110.3448.2227.3525.27
Other Operating Expense0.000.000.000.000.000.00
Operating Income-158.93-169.18-142.60-62.41-29.38-26.35
Interest Expense1.790.490.140.190.070.00
Unusual Expense0.000.650.000.000.000.00
Net Income Before Taxes-152.64-161.31-127.48-60.37-28.89-26.35
Income Taxes0.000.000.000.000.000.00
Consolidated Net Income-152.64-161.31-127.48-60.37-28.89-26.35
Net Income From Continuing Operations-152.64-161.31-127.48-60.37-28.89-26.35
Net Income-152.64-161.31-127.48-60.37-28.89-26.35
EPS (Recurring)-2.51-3.63-3.33-1.40-0.67-0.61
EPS (Basic, Before Extraordinaries)-2.94-3.64-3.33-1.40-0.67-0.61
EPS (Diluted)-2.94-3.64-3.33-1.40-0.67-0.61
EBITDA-157.36-167.38-140.47-60.70-28.33-25.76
Non-Operating Income (Expense)8.099.0115.272.230.56-0.00
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense12.0810.088.362.220.930.25
Gross Margin----85.0489.64
Operating Margin-----418.28-465.81
Net Margin-----411.29-465.88
Shares Outstanding61.5760.3943.2143.1243.1243.12
Market Capitalization314.16314.16161.46157.36--

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.430.350.370.410.520.500.560.56
Gross Profit-0.43-0.35-0.37-0.41-0.52-0.50-0.56-0.56
Selling, General and Administrative Excl. Other39.1241.0238.9138.3143.9046.9140.4838.21
Research and Development24.3529.7229.6530.0435.3036.9332.9228.64
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-39.56-41.37-39.28-38.73-44.41-47.41-41.04-38.77
Interest Expense0.670.670.440.010.010.030.030.03
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-38.32-39.73-37.80-36.79-42.08-44.63-37.49-34.49
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-38.32-39.73-37.80-36.79-42.08-44.63-37.49-34.49
Net Income From Continuing Operations-38.32-39.73-37.80-36.79-42.08-44.63-37.49-34.49
Net Income-38.32-39.73-37.80-36.79-42.08-44.63-37.49-34.49
EPS (Recurring)-0.63-0.66-0.80-0.85-0.97-1.03-0.87-0.80
EPS (Basic, Before Extraordinaries)-0.63-0.66-0.80-0.85-0.97-1.03-0.87-0.80
EPS (Diluted)-0.63-0.66-0.80-0.85-0.97-1.03-0.87-0.80
EBITDA-39.12-41.02-38.91-38.31-43.90-46.91-40.48-38.21
Non-Operating Income (Expense)1.912.311.921.952.342.803.584.31
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.513.172.702.702.522.161.383.41
Shares Outstanding61.5760.5360.3943.7943.2443.2243.2143.17
Market Capitalization314.16521.60537.02259.47132.6883.40161.46210.99

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY
Cash & Short Term Investments279.25285.9857.5451.3276.07
Short Term Receivables0.000.000.000.000.00
Inventories0.000.000.000.000.00
Other Current Assets3.704.623.121.931.02
Total Current Assets282.95290.6060.6653.2577.09
Net Property, Plant & Equipment5.4210.6610.6112.447.81
Total Investments and Advances0.550.550.560.550.55
Deferred Tax Assets1.131.88---
Other Assets4.902.843.360.680.04
Total Assets294.95306.5275.1966.9285.49
Short Term Debt Incl. Current Port. of LT Debt3.973.942.922.280.81
Accounts Payable5.314.624.361.450.77
Other Current Liabilities27.2125.1912.588.2314.34
Total Current Liabilities36.4933.7619.8611.9515.93
Long Term Debt25.064.306.168.294.74
Provision for Risks Charges0.000.000.000.000.00
Deferred Tax Liabilities1.131.88---
Other Liabilities0.000.000.000.012.35
Total Liabilities62.6839.9326.0220.2523.02
Non-Equity Reserves0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.00180.57120.67108.72
Common Equity232.28266.59-131.40-74.00-46.25
Total Shareholders Equity232.28266.5949.1846.6862.47
Accumulated Minority Interest0.000.000.000.000.00
Total Equity232.28266.5949.1846.6862.47
Total Liabilities & Stockholders Equity294.95306.5275.1966.9285.49
Book Value Per Share3.856.17-3.05-1.72-1.07
Tangible Book Value Per Share3.856.17-3.05-1.72-1.07
Full-Time Employees13011296--
Price to Book Ratio1.890.530.52--
Return on Assets-53.64-66.79-84.95-37.91-
Return on Equity-64.67-80.74-125.95-52.95-
Return on Invested Capital-62.68-47.06-109.09-52.57-39.21
Quick Ratio7.758.613.054.454.84
Current Ratio7.758.613.054.454.84

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Net Income-152.64-161.31-127.48-60.37-28.89-26.35
Depreciation1.571.802.131.711.050.59
Other Funds (Non Cash)10.986.873.242.832.068.10
Funds from Operations-140.09-152.64-122.11-55.83-25.79-17.66
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-18.66-1.087.863.42-10.33-4.49
Cash from Operating Activities-158.75-153.71-114.25-52.41-36.11-22.16
Capital Expenditures-1.48-1.13-2.21-0.62-0.77-1.29
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.070.070.000.000.000.00
Purchase or Sale of Investments-7.3941.08-158.70-8.16-13.330.00
Purchase of Investments-336.60-364.62-490.00-54.85-56.490.00
Sale Or Maturity of Investments329.20405.70331.3046.6843.170.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-8.8040.02-160.90-8.79-14.10-1.29
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock122.07117.42338.0758.9012.1372.56
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock122.07117.42338.0758.9012.1372.56
Proceedsfrom Stock Options118.19115.43337.8158.2511.9572.53
Issuance or Reduction of Debt, Net24.3123.89-0.96-0.78-0.25-0.04
Change in Long Term Debt24.3123.89-0.96-0.78-0.25-0.04
Issuance of Long Term Debt24.7024.700.000.000.000.00
Reduction of Long Term Debt-0.39-0.81-0.96-0.78-0.25-0.04
Net Financing Active Other Cash Flow-0.47-0.140.000.000.000.00
Other Financing Activities Uses-0.47-0.140.000.000.000.00
Cash from Financing Activities145.92141.17337.1158.1211.8872.52
Net Change in Cash-21.6327.4761.96-3.08-38.3349.08
Free Cash Flow-160.23-154.84-116.45-53.03-36.88-23.44
Preferred Dividends (Cash Flow)-0.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments199.43236.45279.25171.14211.68242.65
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets7.125.283.703.792.655.00
Total Current Assets206.54241.73282.95174.93214.33247.65
Net Property, Plant & Equipment9.299.735.426.327.588.80
Total Investments and Advances0.550.550.550.550.550.56
Deferred Tax Assets--1.13---
Other Assets3.445.014.905.364.053.64
Total Assets219.82257.02294.95187.16226.51260.65
Short Term Debt Incl. Current Port. of LT Debt1.531.993.973.693.583.58
Accounts Payable2.9311.605.313.029.928.47
Other Current Liabilities18.3416.0927.2127.1726.3021.23
Total Current Liabilities22.8029.6736.4933.8739.7933.29
Long Term Debt31.4731.7725.061.342.343.35
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--1.13---
Other Liabilities0.000.000.000.000.000.00
Total Liabilities54.2761.4462.6835.2142.1336.65
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity165.55195.58232.28151.95184.38224.01
Total Shareholders Equity165.55195.58232.28151.95184.38224.01
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity165.55195.58232.28151.95184.38224.01
Total Liabilities & Stockholders Equity219.82257.02294.95187.16226.51260.65
Book Value Per Share2.693.233.853.474.265.18
Tangible Book Value Per Share2.693.233.853.474.265.18
Full-Time Employees149-130129129-
Price to Book Ratio1.892.242.711.410.590.31
Return on Assets-68.40-60.42-53.64-61.17-53.83-44.70
Return on Equity-87.24-74.55-64.67-70.82-61.29-49.72
Return on Invested Capital-19.45-17.47-14.69-24.00-22.54-19.63
Quick Ratio9.068.157.755.165.397.44
Current Ratio9.068.157.755.165.397.44

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-38.32-39.73-37.80-36.79-42.08-44.63
Depreciation0.430.350.370.410.520.50
Other Funds (Non Cash)3.733.172.171.901.391.40
Funds from Operations-34.15-36.20-35.26-34.47-40.18-42.73
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-6.15-5.391.73-8.858.23-2.18
Cash from Operating Activities-40.31-41.60-33.53-43.32-31.95-44.91
Capital Expenditures-0.550.00-0.54-0.39-0.200.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.070.000.00
Purchase or Sale of Investments36.68-50.20-16.7522.8829.375.58
Purchase of Investments-31.92-115.90-115.95-72.82-94.73-81.12
Sale Or Maturity of Investments68.6065.7099.2095.70124.1086.70
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities36.13-50.20-17.2922.5629.175.58
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock4.070.17116.181.65-0.34-0.07
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock4.070.17116.181.65-0.34-0.07
Proceedsfrom Stock Options2.42-0.07115.840.00-0.34-0.08
Issuance or Reduction of Debt, Net-0.10-0.0924.61-0.12-0.26-0.34
Change in Long Term Debt-0.10-0.0924.61-0.12-0.26-0.34
Issuance of Long Term Debt0.000.0024.700.000.000.00
Reduction of Long Term Debt-0.10-0.09-0.09-0.12-0.26-0.34
Net Financing Active Other Cash Flow-0.19-0.19-0.05-0.04-0.050.00
Other Financing Activities Uses-0.19-0.19-0.05-0.04-0.050.00
Cash from Financing Activities3.79-0.10140.741.49-0.65-0.41
Net Change in Cash-0.39-91.9089.93-19.28-3.43-39.75
Free Cash Flow-40.85-41.60-34.06-43.71-32.15-44.91

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3023.35%9.1M39.0M825.56K
2026-10-1524.50%9.5M39.0M859.47K
2026-09-3024.69%9.6M39.0M921.32K
2026-09-1522.51%8.8M39.0M1.00M
2026-08-3121.93%8.5M38.6M982.89K
2026-08-1422.05%8.5M38.6M1.02M
2026-07-3121.71%8.2M37.7M1.05M
2026-07-1520.83%7.8M37.7M1.19M
2026-06-3019.16%7.2M37.7M1.08M
2026-06-1516.11%6.1M37.7M930.27K
2026-05-2915.28%5.7M37.6M924.46K
2026-05-1514.00%5.3M37.7M873.58K
2026-04-3013.75%5.2M37.5M840.90K
2026-04-1511.63%4.2M36.4M702.22K
2026-03-3112.03%4.2M35.0M751.29K
2026-03-1312.70%4.2M33.1M1.50M
2026-02-2712.66%4.2M33.1M1.45M
2026-02-1311.86%3.9M33.1M1.46M
2026-01-3010.00%3.5M35.1M1.47M
2026-01-159.72%3.4M35.1M1.42M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.204.902.430.00010.000.000.914-0.0320.001
call5.000.001.200.603.4622940.000.633-0.0570.003
call7.500.000.300.052.7702400.000.265-0.0390.003
call10.000.002.000.053.7871320.000.218-0.0470.002
call12.500.004.900.004.6310.000.000.196-0.0570.002
put2.500.000.200.002.9100.000.00-0.042-0.0110.001
put5.000.000.950.563.3165120.00-0.367-0.0570.003
put7.500.102.551.552.6031300.00-0.733-0.0400.003
put10.002.507.403.8111.3620.000.00-0.782-0.0500.002
put12.505.5010.000.0012.3840.000.00-0.804-0.0560.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-19SCHEDULE 13GSEC
2026-09-248-KCurrent report2026-09-24SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-07-29SCHEDULE 13GSEC
2026-07-278-KCurrent report2026-07-23SEC
2026-07-098-KCurrent report2026-07-08SEC
2026-06-028-KCurrent report2026-05-27SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-27SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-27SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-27SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-27SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-27SEC
2026-05-203Initial statement of beneficial ownership of securities2026-05-18SEC
2026-05-204Statement of changes in beneficial ownership of securities2026-05-18SEC
2026-05-188-KCurrent report2026-05-14SEC
2026-05-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-128-KCurrent report2026-05-12SEC
2026-05-064Statement of changes in beneficial ownership of securities2026-05-04SEC
2026-05-063Initial statement of beneficial ownership of securities2026-05-04SEC
2026-05-048-KCurrent report2026-05-04SEC
2026-04-228-KCurrent report2026-04-22SEC
2026-04-228-KCurrent report2026-04-21SEC
2026-04-208-KCurrent report2026-04-20SEC
2026-04-17144Filing for proposed sale of securities under Rule 144.SEC
2026-04-14144Filing for proposed sale of securities under Rule 144.SEC
2026-04-13ARSAnnual report to security holders. 2025-12-31SEC
2026-04-13DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-13DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-05-27SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-122.00M2292.78K1
2025-110000

Institutional holders

Manager% owned
GordonMD Global Investments LP6.98%
GILEAD SCIENCES, INC.6.67%
AIGH Capital Management LLC5.90%
BlackRock, Inc.5.16%
Bain Capital Life Sciences Investors, LLC4.75%
DEERFIELD MANAGEMENT COMPANY, L.P.3.29%
VANGUARD CAPITAL MANAGEMENT LLC3.12%
PRICE T ROWE ASSOCIATES INC /MD/1.95%
GEODE CAPITAL MANAGEMENT, LLC1.70%
Insight Holdings Group, LLC1.63%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.31%
iShares Russell 2000 ETF1.77%
T. Rowe Price Health Sciences Fund, Inc.1.41%
Fidelity Small Cap Index Fund0.75%
VANGUARD EXTENDED MARKET INDEX FUND0.74%
iShares Russell 2000 Value ETF0.58%
iShares Biotechnology ETF0.44%
State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF0.43%
VANGUARD RUSSELL 2000 INDEX FUND0.39%
Simplify Propel Opportunities ETF0.30%

OakChart. KYTX. Cached 15 minutes.